कृपया अन्य खोज का प्रयास करें
चिन्ह | एक्सचेंज | करेंसी | ||
---|---|---|---|---|
4568 | टोक्यो | JPY | देरी | |
DSNKY | OTC Markets | USD | देरी | |
4568 | फ़्रंकफ़र्ट | EUR | देरी |
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Sawako Nohara | 65 | 2019 | Independent Outside Director |
Masako Watanabe | 61 | 2021 | Outside Audit & Supervisory Board Member |
Sunao Manabe | 69 | 2009 | Group CEO & Executive Chairperson |
Yukiko Imazu | 55 | 2018 | Outside Audit & Supervisory Board Member |
Kama Kazuaki | 75 | 2019 | Independent Outside Chairperson |
Miyuki Arai | 60 | 2019 | Member of Audit & Supervisory Board |
Yasuhiro Komatsu | 66 | 2022 | Independent Outside Director |
Mitsuhiro Matsumoto | 62 | 2022 | Outside Audit & Supervisory Board Member |
Kenji Sato | 60 | 2019 | Chairman of Audit & Supervisory Board |
Takaaki Nishii | 64 | 2023 | Independent Outside Director |
Shoji Hirashima | 62 | 2017 | Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director |
Masahiko Ohtsuki | 64 | 2014 | Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director |
Hiroyuki Okuzawa | 61 | 2018 | President, COO & Representative Director |
Takashi Fukuoka | 63 | 2022 | Senior Managing Exec. Officer, Global Head of Corporate Strategy, Chief Strategy Officer & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है